Neuren Pharmaceuticals (NEU.AX) Earnings Analysis

Neuren Pharmaceuticals (NEU.AX) next reports earnings on 2026-08-25, consensus EPS 0.07451 AUD. Last quarter (2025-08-26) it beat with EPS 0.1165 AUD vs 0.1165 AUD est (0%). It has beaten estimates in 1/2 recent quarters (50%). Trailing P/E 68.58.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does NEU.AX next report earnings?

Next earnings date2026-08-25
Consensus EPS estimate0.07451 AUD
Revenue estimate0.03B

NEU.AX earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2025-08-260.1165 AUD0.1165 AUD0%Beat
2025-02-271.03 AUD1.04 AUD-1%Miss

Beat rate: 1/2 (50%) over reported quarters with consensus data.

NEU.AX valuation and analyst view

Trailing P/E68.58
Trailing EPS0.24034 AUD
Price / book6.16
Dividend yield0.00%
Market cap2.19B

Limited or no published sell-side analyst coverage for this symbol.

Related research pages

Frequently asked questions

When is Neuren Pharmaceuticals (NEU.AX)'s next earnings date?

Neuren Pharmaceuticals is next scheduled to report on 2026-08-25, with a consensus EPS estimate of 0.07451 AUD and revenue estimate of 0.03B.

Did NEU.AX beat earnings last quarter?

In its 2025-08-26 report, NEU.AX posted EPS of 0.1165 AUD versus a 0.1165 AUD estimate — a beat of 0%.

What is NEU.AX's earnings track record?

Over the last 2 reported quarters with consensus data, NEU.AX beat estimates 1 times (50%).

What is NEU.AX's current P/E ratio and EPS?

NEU.AX trades at a trailing P/E of 68.58 on trailing EPS of 0.24033570687875128 AUD.

What do analysts rate NEU.AX?

NEU.AX has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.